Colistin Pharmacokinetics in Continuous Renal Replacement Therapy
NCT ID: NCT02081560
Last Updated: 2014-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
10 participants
INTERVENTIONAL
2013-11-30
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis:no dose reduction is needed in patients undergoing continuous renal replacement therapy over 24h because colistin is sufficiently removed by this procedure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Colistin Pharmacokinetics in Critically Ill Patients During Extended Dialysis
NCT02556190
Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.
NCT04995133
Safety and Therapeutic Drug Monitoring of Cefazolin in Continuous Renal Replacement Therapy
NCT03672149
Safety and TDM of Continuous Infusion Vancomycin Through Continuous Renal Replacement Therapy Solution
NCT02663596
Optimization Dose Study on Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients
NCT02408185
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients are monitored for signs of neuro- and nephrotoxicity
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
colistin pharmacokinetics
Intravenous colistin 9 million units loading dose and 3 million units q8h maintenance dose as long as treatment of infection is required
Colistin
Colistin i.v. three times daily as long a necessary for infection treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Colistin
Colistin i.v. three times daily as long a necessary for infection treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* hospitalised on the ICU
* gram-negative infection requiring antibiotic therapy with intravenous colistin as part of their routine medical care
* clinical necessity for continuous venovenous renal replacement therapy
Exclusion Criteria
* Personal or family history of Myasthenia Gravis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Natascia Corti, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Zurich, Dept. of Pharmacology and Toxicology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Zurich, Dept. of Pharmacology and Toxicology
Zurich, Canton of Zurich, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Leuppi-Taegtmeyer AB, Decosterd L, Osthoff M, Mueller NJ, Buclin T, Corti N. Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy. Antimicrob Agents Chemother. 2019 Jan 29;63(2):e01957-18. doi: 10.1128/AAC.01957-18. Print 2019 Feb.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
213DR11032
Identifier Type: OTHER
Identifier Source: secondary_id
COLPKZH11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.